LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

ADMISSION TO SPECIAL EXAMINATION AND APPROVAL PROCEDURE FOR INNOVATIVE MEDICAL DEVICES IN RESPECT OF FUTHROUGH™ ENDOVASCULAR NEEDLE SYSTEM

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 17 April 2020, the Company obtained formal approval from National Medical Products Administration ("**NMPA**") confirming the admission of Futhrough™ Endovascular Needle System (also known as ENS) (the "**Product**") to NMPA Special Examination and Approval Procedure for Innovative Medical Services (藥監局創新醫療器械特別審批程序) (the "**Procedure**"). The Product is the tenth product of the Company having obtained admission to the Procedure.

Futhrough™ Endovascular Needle System is an In-situ fenestration ("**ISF**") device for puncturing the membrane (fenestration) of aorta stent graft at the ostium of the revascularized artery using the fenestration technique. The Product consists of a catheter and a puncture needle. The puncture needle is comprised of a needle, a flexible metal tubing and a handle. By connecting the tubing to the puncture needle, the Product can adapt to the tortuous vessels branched from aortic arch and provide a guidewire passage, so as to facilitate guidewire entry after puncturing. The puncture handle can adjust puncture depth to avoid unintentional injury of the vessels. This Product has the advantages of simple operation, better puncture efficiency, excellent dissection adaptability, and applicable to a wider range of diseases.

The ISF technique refers to the use of special fenestration device for puncturing the membrane of aorta stent graft at the ostium of the revascularized artery, and forming a window for blood circulation via the puncture point expanded by a balloon dilation, followed by the implantation of branch stent to ensure patency of the window to complete the revascularization at the aortic arch branch. The technique has several advantages in maintaining the physiological blood flow, minimizing risks of endohemorrhage and is relatively simple for positioning, and is one of the effective endovascular interventional methods involving aortic arch pathological changes.

When performing the ISF technique, the combination of the Product and the Company's aortic arch stent graft system (ie, Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System) provides an effective solution for pathological changes in aortic arch due to complexed forms of dissection, insufficient space for anchorage and difficulties in the retention of branch vessels, to offer a safer and more effective endovacular intervention solution to patients suffering from aortic arch pathological changes.

The Board believes that the admission of the Procedure will be beneficial to the Company in furthering the registration process of the Product, whereby accelerating its launching process in China, and facilitating the research and clinical work of the Company on the aortic arch stent graft system, so as to benefit the patients suffering from aortic arch pathological changes. At the same time, it will further enrich and improve the product layout innovation of the Group's endovacular interventional devices, which promotes the long-term stable development of the Group.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and
Chief Executive Officer

Hong Kong, 22 April 2020

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng and Mr. FU Feng being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.